Theratechnologies Inc.

Daniel Abran

Krishna G Peri

Serge Moffett

Abdelkrim Habi

Annie Bergeron

Novel GLP-1 analogs having improved biological potency as well as extended pharmacological activity are described herein. More specifically, the present invention relates to GLP-1 analogs (28 or 29 aa long) comprising amino acid substitutions at one or more of the following positions: 8, 20, 27, 30 and 33.

Glucagon-like peptide-1 analogs with long duration of action

Antagonistic peptides of prostaglandin E2 receptor subtype EP4 and their use in the treatment or prevention of medical conditions associated with oligouric nephropathy, bone resorption, abnormal intestinal crypt cell proliferation or patency of the ductus arteriosus and the like are provided herein. The antagonistic peptides of the present invention can include the following formula:X-A-RYwherein 'X' is a hydrogen atom or an amine protecting group producing a carbamate or an amide when reacting with the amine; 'A' is L-(4,4')-biphenylalanine or D-(4,4&#x2032;)-biphenylalanine; &#x201c;R&#x201d; is an amino acid selected from the group consisting of threonine, serine, tyrosine, glutamic acid, alanine, leucine and glycine; &#x201c;Y&#x201d; is lysine; &#x201c;n&#x201d; is an integer ranging from 5 to 7; and &#x201c;m&#x201d; is an integer ranging from 0 to 2.

Antagonistic peptides of prostaglandin E2 receptor subtype EP4

A GPCR-like protein is described, as well as inhibitory/antagonistic compounds and compositions comprising such inhibitors/antagonists of the protein. Such compounds may be used for treating elevated intraocular pressure and conditions associated with elevated intraocular pressure, such as glaucoma.

Growing community of inventors

Vaudreuil, Canada

Daniel Abran